Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples